Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 16/20 | 0.47 |
| ▸ | XIAP | P98170 | 2/20 | 0.40 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15569795 | 0.91 | GHSR (0.49) | GHSRXIAP | |
| SCHEMBL15569752 | 0.89 | GHSR (0.42) | GHSRXIAP | |
| SCHEMBL15569633 | 0.85 | XIAP (0.54) | GHSRXIAP | |
| SCHEMBL16930770 | 0.81 | XIAP (0.37) | GHSRXIAP | |
| SCHEMBL16930745 | 0.81 | XIAP (0.37) | GHSRXIAP | |
| SCHEMBL15569738 | 0.80 | XIAP (0.60) | GHSRXIAP | |
| SCHEMBL15569060 | 0.80 | GHSR (0.41) | GHSRXIAP | |
| SCHEMBL8417697 | 0.80 | GHSR (0.51) | GHSRFNTAFNTB | |
| SCHEMBL8276148 | 0.80 | GHSR (0.51) | GHSRFNTAFNTB | |
| SCHEMBL8224318 | 0.79 | GHSR (0.54) | GHSRFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422332-B2 | Azaheterocycles as BIR2 and/or BIR3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150210739-A1 | AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-07-30 | — | — | US | disclosed |
| EP-2885275-A1 | AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014026882-A1 | AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210739-A1 | AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS | BIRC3, BIRC5, BIRC2 | GHSR 4702/4885XIAP 4/4885FNTA 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.